Rajshekhar Chakraborty is an Oncology physician affiliated with Columbia University Irving Medical Center. OpenAlex indexes 295 publications with 2,855 citations (h-index 28); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
161 Fort Washington Ave
New York, NY 100323729
Telephone
212-305-5098Provider last certified this registry record 24 Feb 2023.
Clinical trials
- Teclistamab-Daratumumab in AL Amyloidosis
Sponsor: Rajshekhar Chakraborty, MD
- Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
Sponsor: Columbia University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20257 payments
- Regeneron Pharmaceuticals, Inc.Program year20258 payments
- PFIZER INC.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
100%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor100%Valacyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Blood Cancer Journal
2024 - Dietary interventions in cancer: a systematic review of all randomized controlled trials
JNCI Journal of the National Cancer Institute
2024 - Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review
Blood Cancer Journal
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Stanley Fahn, MD
Columbia University Irving Medical Center
Rebecca Hahn, MD
Columbia University Irving Medical Center
Susheel Kodali, MD
Columbia University Irving Medical Center
Ronald Wapner, MD
Columbia University Irving Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”